Elevated serum levels of neuropeptide Y in stress cardiomyopathy

Szardien, Sebastian; Möllmann, Helge; Voβ, Sandra; Troidl, Christian; Rolf, Andreas; Liebetrau, Christoph; Rixe, Johannes; Elsässer, Albrecht; Hamm, Christian W.; Nef, Holger

doi:10.1016/j.ijcard.2010.05.010

Cited by 15 publications

(15 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We agree with the authors that increased serum NPY levels may contribute to myocardial contractile dysfunction and hence may also be regarded as a prognostic marker in patients with SCM [1]. However, in the setting of SCM with substantial NPY levels, NPYinduced coronary microvascular dysfunction, as described below, may also contribute significantly to the adverse clinical outcomes including ischemic malign arrhythmias, etc.…”

supporting

confidence: 84%

“…In their recently published article, Szardien et al reported a 78-year-old female patient who had suffered stress cardiomyopathy (SCM) accompanied by increased serum levels of neuropeptide Y (NPY) [1]. We agree with the authors that increased serum NPY levels may contribute to myocardial contractile dysfunction and hence may also be regarded as a prognostic marker in patients with SCM [1].…”

supporting

confidence: 61%

See 1 more Smart Citation

Neuropeptide Y-induced coronary microvascular dysfunction: A significant contributor to the adverse outcomes in stress cardiomyopathy?

Yalta

Sivri

Yalta

2011

International Journal of Cardiology

View full text Add to dashboard Cite

supporting

confidence: 84%

supporting

confidence: 61%

Neuropeptide Y-induced coronary microvascular dysfunction: A significant contributor to the adverse outcomes in stress cardiomyopathy?

Yalta

Sivri

Yalta

2011

International Journal of Cardiology

View full text Add to dashboard Cite

“…Drug‐related prevention of LV fibrotic remodeling was significantly correlated with altered levels of a known DPP‐4 substrate, neuropeptide Y (NPY). NPY levels are increased in disease states in which sympathetic nervous system activation is enhanced, such as diabetic or stress cardiomyopathy,33, 34 and our results show a significant increase in circulating plasma NPY in the HF group. Neuropeptide Y is positively correlated in humans with LV wall thickness, LV mass index, and associated with a higher risk of concentric hypertrophy 35, 36.…”

Section: Discussionsupporting

confidence: 55%

Saxagliptin and Tadalafil Differentially Alter Cyclic Guanosine Monophosphate (cGMP) Signaling and Left Ventricular Function in Aortic‐Banded Mini‐Swine

Hiemstra

Lee

Chakir

et al. 2016

JAHA

View full text Add to dashboard Cite

BackgroundCyclic guanosine monophosphate‐protein kinase G‐phosphodiesterase 5 signaling may be disturbed in heart failure (HF) with preserved ejection fraction, contributing to cardiac remodeling and dysfunction. The purpose of this study was to manipulate cyclic guanosine monophosphate signaling using the dipeptidyl‐peptidase 4 inhibitor saxagliptin and phosphodiesterase 5 inhibitor tadalafil. We hypothesized that preservation of cyclic guanosine monophosphate cGMP signaling would attenuate pathological cardiac remodeling and improve left ventricular (LV) function.Methods and ResultsWe assessed LV hypertrophy and function at the organ and cellular level in aortic‐banded pigs. Concentric hypertrophy was equal in all groups, but LV collagen deposition was increased in only HF animals. Prevention of fibrotic remodeling by saxagliptin and tadalafil was correlated with neuropeptide Y plasma levels. Saxagliptin better preserved integrated LV systolic and diastolic function by maintaining normal LV chamber volumes and contractility (end‐systolic pressure‐volume relationship, preload recruitable SW) while preventing changes to early/late diastolic longitudinal strain rate. Function was similar to the HF group in tadalafil‐treated animals including increased LV contractility, reduced chamber volume, and decreased longitudinal, circumferential, and radial mechanics. Saxagliptin and tadalafil prevented a negative cardiomyocyte shortening‐frequency relationship observed in HF animals. Saxagliptin increased phosphodiesterase 5 activity while tadalafil increased cyclic guanosine monophosphate levels; however, neither drug increased downstream PKG activity. Early mitochondrial dysfunction, evident as decreased calcium‐retention capacity and Complex II‐dependent respiratory control, was present in both HF and tadalafil‐treated animals.ConclusionsBoth saxagliptin and tadalafil prevented increased LV collagen deposition in a manner related to the attenuation of increased plasma neuropeptide Y levels. Saxagliptin appears superior for treating heart failure with preserved ejection fraction, considering its comprehensive effects on integrated LV systolic and diastolic function.

show abstract

“…For the development of peptidomic biomarker candidates, we screened 12 peptides which have been reported to be elevated in the elderly populations. 30,31 Among 12 targeted peptides, 4 peptides (NPY, NFMLP, SubP, and BNP(47-76)) were detected in the first screening of AMI patient samples. The qualitative analysis of peptide standards and patient samples showed same retention times and mass fragmentation patterns.…”

Section: Resultsmentioning

confidence: 99%

Substance P and Neuropeptide Y as Potential Biomarkers for Diagnosis of Acute Myocardial Infarction in Korean Patients

Han¹,

Seo²,

Jung³

et al. 2014

Bulletin of the Korean Chemical Society

View full text Add to dashboard Cite

Substance P and neuropeptide Y were discovered as early diagnostic biomarkers of acute myocardial infarction in Korean patients and confirmed using enzyme-linked immunosorbent assay (ELISA). We screened 12 peptides from the sera of Korean acute myocardial infarction (AMI) patients and detected 3 peptides (neuropeptide Y, substance P, and N-terminal pro-B-type natriuretic peptide) to be elevated from patients' sera by liquid chromatography mass/mass spectrometry. The elevated concentration of 3 peptides was confirmed by ELISA. The screening results revealed the substance P, neuropeptide Y, and pro-B-type natriuretic peptide (47-76) concentrations were higher in patients' sera than in healthy controls. The sensitivity and specificity of substance P for AMI diagnostic marker were 80% and 83%, respectively, and those of neuropeptide Y were 87% and 90%, respectively compared to healthy controls. These results suggest that substance P and neuropeptide Y could be used as early diagnostic biomarkers in patients with AMI.

show abstract

Elevated serum levels of neuropeptide Y in stress cardiomyopathy

Cited by 15 publications

References 23 publications

Neuropeptide Y-induced coronary microvascular dysfunction: A significant contributor to the adverse outcomes in stress cardiomyopathy?

Neuropeptide Y-induced coronary microvascular dysfunction: A significant contributor to the adverse outcomes in stress cardiomyopathy?

Saxagliptin and Tadalafil Differentially Alter Cyclic Guanosine Monophosphate (cGMP) Signaling and Left Ventricular Function in Aortic‐Banded Mini‐Swine

Substance P and Neuropeptide Y as Potential Biomarkers for Diagnosis of Acute Myocardial Infarction in Korean Patients

Contact Info

Product

Resources

About